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Sir,
Enderling et al (2009) describe simulated tumour growth using an
in silico model comprised of cancer stem and non-stem cells. Using
this model, three kinetic parameters at the cellular level (cell death,
proliferation and migration linked to the space available for
growth) can be controlled to explain the population-level features
of tumour growth, even in the absence of a heterogeneous
environment. The results collectively show that migratory ability
dominates tumour growth kinetics. Insufficient cell death or
long-living non-stem progeny, both resulting in space constraints,
impede migration and symmetrical stem cell division, and, in
this way, tumour progression. The spatiotemporal evolution of the
model is characterised by the phenomenon of self-metastasis
(Norton and Massague, 2006), i.e., tumour growth with cluster
formation, with only the stem-cell-initiated clusters persisting.
Inflammatory breast cancer (IBC) belongs to the clinical group
of locally advanced breast cancers, with an unfavourable outcome.
Although a relatively rare entity (only about 5% of all patients with
breast cancer have IBC), worldwide several groups have focused
their research on IBC for the following reasons: (1) the therapeutic
opportunities are limited and new approaches need to be
developed; (2) awareness needs to be increased among health
workers because early diagnosis improves the outcome; and (3)
IBC can function as a model of fast local growth, because cancer
cell populations occupy large fractions of the breast gland within
weeks to months, and as a model of efficient metastasis, because
almost all patients have lymph node metastases and about one-
third have distant metastases at diagnosis.
In this context, we would like to suggest that the biological
features of IBC strongly support the in silico model of self-
metastatic expansion as demonstrated by Enderling et al (2009).
From a pathologist’s point of view, IBC has a specific growth
pattern with a central tumour mass surrounded by smaller nodules
of carcinoma, which is in continuity with the central tumour and
resembles the three-dimensional simulation of Figure 7 in
Enderling’s paper, but is also spread throughout the breast tissue
and even in the dermis. The latter distant nodules are separated
from the main tumour and from each other by normal breast
parenchyma, and can be regarded as metastases within the breast.
IBC is thus ‘less compact’ than non-IBC, leaving more available
space for migration of cancer cells.
The growth pattern of IBC clearly fits the self-metastatic
expansion hypothesis, and additional histological characteristics
and the results of molecular studies of IBC further support this. In
the breast parenchyma separating the tumour nodules, numerous
intravascular tumour emboli can be observed, which is a well-
established hallmark of IBC. Small areas of invasive carcinoma
sometimes surround the intravascular tumour emboli. Regarding
the kinetic parameters of the cellular level of the Enderling model,
we propose that tumour emboli in blood vessels and lymph vessels
represent significant cell movement throughout the breast gland,
with a high m value, through growth in the intravascular space. This
intravascular growth has been observed in the MARY-X animal
model of IBC and is based on strong homotypic interactions
between the tumour cells by overexpression of E-cadherin (Alpaugh
et al, 1999). Extravasation can occur actively, or, passively by
volume increase resulting in rupture of the vessel wall, giving rise to
a self-metastatic clone. In addition to the efficient migration of
tumour cells in the vasculature of the breast gland, genome-wide
gene expression profiling shows that IBC has overexpressed
signalling pathways related to cell migration, which can lead to
the ‘fingering morphologies’ at the edge of the main tumour mass.
The insulin-like growth factor signalling is increased in IBC (Van
Laere et al, 2007), leading to RhoC activation, one of the first
molecular alterations that has been related to IBC and is responsible
for increased cell motility (van Golen et al, 1999). NF-kBu p -
regulation, another established molecular characteristic of IBC,
enhances tumour cell migration by inducing the mesenchymal cell
behaviour of epithelial cells (Van Laere et al,2 0 0 6 ) .
An equally important condition in the self-metastasis model
is the presence of cancer stem cells that are capable of migrating
in less dense space to form separate tumour cell clusters; in
the in silico model, only clones initiated by such stem cells survive.
IBC clearly complies with these conditions as well. The lympho-
vascular emboli in animal models of IBC express a stem cell-like
phenotype (Xiao et al, 2008). In human samples of IBC, the emboli
are large and often have central necrosis and express CAIX as a
marker of hypoxia, a condition in favour of a stem cell niche
(Colpaert et al, 2003) The gene expression signature of IBC in
patients contains stem cell gene expression patterns (Van Laere
et al, 2008). Published online 25 August 2009
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the breast gland, combined with a specific growth pattern
(intravascular tumour expansion and enhanced cell migration)
and numerous metastases at diagnosis, corroborates the self-
metastatic expansion model. The design of a new multimodality
treatment for patients with IBC, and with breast cancer in general,
probably has to implement the interactions of the treatment with
the balance between proliferation and cell death, on the one hand,
and migration in available space, on the other hand, taking into
account both the stem and non-stem cell populations.
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